Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Neuroimaging and neurophysiology
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To assess the associations of presynaptic dopamine transporter (DAT scan), cardiac 123I-meta-iodobenzylguanidine (MIBG) scintigraphy, and cerebrospinal fluid (CSF) levels of 5-hydroxyindole acetic acid (5HIAA) in Parkinsoninan syndrome patients, including Parkinson’s disease (PD).
Background: Several multi-center studies including the Parkinson’s Progression Markers Initiative have established standardized methods of acquisition and analysis of biomarker data. Biomarkers for diagnosis and prognosis of PD have not been identified.
Methods: We evaluated 41 patients with Lewy body disease (LBD; PD, PD with dementia, and dementia with Lewy bodies; age, mean±SD: 75.7±15.9 years), three patients with Progressive Supranuclear Palsy (PSP; 71.3±14.1 years), four patients with Multiple System Atrophy (MSA; 73.8±27.4 years), eight patients with corticobasal syndromes (CBS; 79.1±6.1 years), one patient with vascular parkinsonism (83 years), and one patient with drug induced parkinsonism (68 years). All subjects underwent DAT scan imaging, MIBG scintigraphy, and CSF analysis of 5HIAA levels.
Results: Significant differences were observed in the median heart mediastinum ratio (H/M) of MIBG between LBD and other Parkinsonian syndromes (MSA, PSP, and CBS; p < 0.001). CSF 5HIAA levels were significantly different between LBD and other Parkinsonian syndromes (p < 0.05). However, no differences were seen in the specific binding ratio (SBR) of the DAT scan. We found no significant difference between groups (SBR of the DAT scan and H/M of MIBG, H/M and CSF 5HIAA levels, and SBR of the DAT scan and CSF 5HIAA levels; coefficients = 0.32, 0.34, and 0.15, respectively).
Conclusions: MIBG scintigraphy or CSF 5HIAA levels can differentiate between LBD and other Parkinsonian syndromes. SBR of the DAT scan may be useful as part of the differential diagnosis of Parkinsonian syndrome.
To cite this abstract in AMA style:
R. Sengoku, M. Yamazaki, D. Kaneda, Y. Nishina, A.M. Tokumaru, S. Murayama. Comparison of DAT scan, cardiac MIBG scintigraphy, and cerebrospinal fluid 5HIAA levels in Parkinsonian syndrome [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/comparison-of-dat-scan-cardiac-mibg-scintigraphy-and-cerebrospinal-fluid-5hiaa-levels-in-parkinsonian-syndrome/. Accessed June 14, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/comparison-of-dat-scan-cardiac-mibg-scintigraphy-and-cerebrospinal-fluid-5hiaa-levels-in-parkinsonian-syndrome/